AstraZeneca Pharma India Reports 33% YoY Revenue Growth
AstraZeneca Pharma India Limited Announces FY 2025‑26 Annual Results
Bangalore, 26 May 2026 – AstraZeneca Pharma India Limited (the “Company”) released its full‑year financial and operational results for the fiscal year ended 31 March 2026. The filing highlights a 33 % year‑on‑year increase in total revenue and a suite of regulatory approvals that expand the Company’s therapeutic portfolio in India.
Financial Performance Highlights
| Metric | FY 2025‑26 (Apr ’25‑Mar ’26) | Q4 2026 (Jan‑Mar) |
|---|---|---|
| Total revenue from operations | ₹ 22,755.8 Mn | ₹ 5,786.1 Mn |
| Profit before exceptional items & tax | ₹ 2,574.5 Mn | ₹ 592.2 Mn |
| Profit after exceptional items & tax | ₹ 1,875.2 Mn | ₹ 448.8 Mn |
- Revenue growth: 33 % YoY, driven by sustained performance across Oncology, Biopharmaceuticals, and Rare Disease segments.
- Profitability: Both pre‑tax and post‑tax profits rose sharply, reflecting disciplined execution and margin expansion.
Therapy‑Area Revenue Breakdown (Full FY)
| Therapy Area | Revenue (₹ Mn) |
|---|---|
| Oncology | 16,100.9 |
| Biopharmaceuticals (CVRM, R&I, V&I) | 5,243.2 |
| Rare Disease | 214.6 |
Regulatory Approvals & Product Milestones
AstraZeneca India secured 11 new regulatory approvals in FY 2025‑26, enhancing patient access to innovative medicines:
- Durvalumab – Endometrial cancer (first‑line + maintenance); Muscle‑invasive bladder cancer (adjuvant).
- Durvalumab – Gastric cancer (peri‑operative, FLOT combo) and Liver cancer (first‑line with tremelimumab).
- Eculizumab – First anti‑complement therapy in India for atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
- Osimertinib – Additional NSCLC indications: (i) with pemetrexed + platinum (first‑line); (ii) monotherapy for stage III disease post‑chemoradiation.
- Trastuzumab deruxtecan – HER2‑low/ultralow metastatic breast cancer (post‑endocrine therapy).
- Benralizumab – Add‑on therapy for eosinophilic granulomatosis with polyangiitis (EGPA).
- Sodium Zirconium Cyclosilicate (5 g/10 g) – Hyperkalaemia management (partnered with Sun Pharma).
These approvals reinforce AstraZeneca’s leadership across its core therapy areas and accelerate the delivery of innovative medicines to Indian patients.
Management Commentary
Bhavana Agrawal, CFO & Director:
“FY 2025‑26 was a year of strong and consistent growth… our performance reflects commercial momentum and our commitment to sustainable value through innovation, responsible growth, and meaningful impact for patients, society, and the planet.”
Praveen Rao Akkinepally, Managing Director:
“Science is at the heart of everything we do. Our FY 2025‑26 performance reflects the progress we are making, accelerating the delivery of innovative medicines across key therapy areas and advancing our ambition to transform patient outcomes in India.”
Awards & Recognitions
- Pharma Company of the Year – ET RePharma Awards
- Medical Excellence Award for Rare Disease – OPPI India
- Top Employer India 2025
- Marketing Excellence Award (Hyperkalaemia & Kidney Care, Biopharmaceuticals) – OPPI India
- OPPI Medical Excellence Awards 2025 – Medical Affairs, Regulatory Excellence, Clinical Trials
- 1st Place, 2025 SAS Customer Recognition Awards – Innovative use of Real‑World Data in clinical trials
- ET HRWorld EX Awards 2025 – Exceptional Employee Experience (Large Scale)
- Excellence in Precision Biopharma Solutions – VOH National Healthcare Awards 2025
The information above is extracted directly from AstraZeneca Pharma India Limited’s FY 2025‑26 results announcement dated 26 May 2026.
Original Source Document
View the original exchange filing or announcement.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka